GlobalData on MSN6h
J&J’s fully subcutaneous Tremfya shows 27.6% clinical remission in UC
Tremfya was administered subcutaneously for both induction and maintenance, inducing a clinical response in 65% of moderate ...
Teva Pharma and Alvotech launch biosimilar to J&J's Stelara in US
Teva Pharmaceuticals and Alvotech said on Friday they have launched a biosimilar to Johnson & Johnson's autoimmune drug ...
JNJ met main goal in late-stage trial for ulcerative colitis treatment
Johnson & Johnson (JNJ) said on Friday that its late-stage study of TREMFYA as an induction therapy for adults with ...
TMCnet11h
Iterative Health to Present AI Advancements at ECCO 2025, Highlighting Potential to Evolve Ulcerative Colitis Clinical Trial Endpoints
"There is a pressing need to modernize traditional endoscopic assessments in IBD to enhance precision and efficiency in ulcerative colitis research," said Mark Genovese, MD, Senior Vice President of ...
Microbiotica unveils data on the mechanism of action of MB310, a clinical-stage drug candidate in development for the treatment of ulcerative colitis
Data presented at key congresses in North America and EuropeCAMBRIDGE, United Kingdom, Feb. 21, 2025 (GLOBE NEWSWIRE) -- ...
manilatimes13h
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
SELARSDI is approved for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in adults and ...
Medscape16h
Antibiotics Getting False Blame for Colitis, Study Finds
A nationwide study of older adults in Sweden suggests a suspected link between antibiotic use and microscopic colitis is more ...